The online version of this article (https://doi.org/10.1007/s12325-018-0831-9) contains supplementary material, which is available to authorized users.
To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.7257275.
Tiotropium bromide has been widely used in clinical practice, while theophylline is another treatment option for chronic obstructive pulmonary disease (COPD). However, only a few relevant studies have investigated the long-term outcomes and efficacy of both in patients with COPD. We evaluated the effects of tiotropium and low-dose theophylline on stable COPD patients of groups B and D.
Eligible participants (n = 170) were randomized and received either tiotropium 18 µg once daily with theophylline 100 mg twice daily (Group I) or tiotropium 18 µg once daily (Group II) for 6 months. COPD assessment test (CAT), modified Medical Research Council (mMRC) dyspnea scores and pulmonary function tests were measured before randomization and during the treatment.
After 6 months of treatment, the CAT scores in both groups decreased significantly (11.41 ± 3.56 and 11.08 ± 3.05, p < 0.0001). The changes of CAT (p = 0.028) and mMRC scores (p = 0.049) between the two groups differed after 1 month of treatment. In Group I, forced expiratory flow after 25% of the FVC% predicted (MEF25% pred) was significantly improved after 3 months (4.84 ± 8.73%, p < 0.0001) and 6 months (6.21 ± 8.65%, p < 0.0001). There was a significant difference in small airway function tests (MEF50% pred, MEF25% pred, and MMEF% pred) between the two groups after 6 month of treatment (p = 0.003, p < 0.0001, and p = 0.021, respectively).
Tiotropium combined with low-dose theophylline significantly improved the symptoms and general health of patients with stable COPD of groups B and D after 6 months of follow-up. Additionally, this therapy also improved the indicators of small airway function.
Chinese Clinical Trial Registry (Registry ID: ChiCTR1800019027).
Supplementary material 1 (DOC 121 kb)12325_2018_831_MOESM1_ESM.doc
Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2017 report [EB/OL](2016-11-16). http://www.goldcopd.org. Accessed 3 Jan 2017.
Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442. https://doi.org/10.1371/journal.pmed.0030442. CrossRefPubMedPubMedCentral
Global strategy for the diagnosis, management, and prevention of COPD (revised 2011) [EB/OL] (2011-11). http://www.goldcopd.org. Accessed 2 Jan 2011.
Vestbo J, Vogelmeier C, Small M, Higgins V. Understanding the GOLD 2011 strategy as applied to a real-world COPD population. Resp Med. 2014;108(5):729–36. https://doi.org/10.1016/j.rmed.2014.03.002. CrossRef
Jones PW, Nadeau G, Small M, Adamek L. Characteristics of a COPD population categorised using the GOLD framework by health status and exacerbations. Resp Med. 2014;108(1):129–35. https://doi.org/10.1016/j.rmed.2013.08.015. CrossRef
Han MLK, Muellerova H, Curran-Everett D, Dransfield MT, Washko GR, Regan EA, Bowler RP, Beaty TH, Hokanson JE, Lynch DA, Jones PW, Anzueto A, Martinez FJ, Crapo JD, Silverman EK, Make BJ. GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Resp Med. 2013;1(1):43–50. https://doi.org/10.1016/S2213-2600(12)70044-9. CrossRef
Soriano JB, Alfageme I, Almagro P, Casanova C, Esteban C, Soler-Cataluna JJ, de Torres JP, Martinez-Camblor P, Miravitlles M, Celli BR, Marin JM. Distribution and prognostic validity of the New Global Initiative for Chronic Obstructive Lung Disease grading classification. Chest. 2013;143(3):694–702. https://doi.org/10.1378/chest.12-1053. CrossRefPubMed
Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA, Investigators I. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19–26. https://doi.org/10.1164/rccm.200707-973OC. CrossRefPubMed
Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP, Investigators U. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374(9696):1171–8. https://doi.org/10.1016/S0140-6736(09)61298-8. CrossRefPubMed
Kanehara M, Yokoyama A, Tomoda Y, Shiota N, Iwamoto H, Ishikawa N, Taooka Y, Haruta Y, Hattori N, Kohno N. Anti-inflammatory effects and clinical efficacy of theophylline and tulobuterol in mild-to-moderate chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2008;21(6):874–8. https://doi.org/10.1016/j.pupt.2008.09.003. CrossRefPubMed
Berger R, Smith D. Acute postbronchodilator changes in pulmonary function parameters in patients with chronic airways obstruction. Chest. 1988;93(3):541–6. CrossRef
Global strategy for the diagnosis, management, and prevention of COPD, update January 2015 [EB/OL]. http://www.goldcopd.org. Accessed 3 Jan 2015.
Sampablo I, Carone M, Antoniu SA. Tiotropium therapy and mortality risk in COPD patients: the most severe, the most protected? Evaluation of Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180(10): 948-55. Expert Opin Pharmacother. 2010;11(8):1439–41. https://doi.org/10.1517/14656561003745916. CrossRefPubMed
Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;9:CD009157. https://doi.org/10.1002/14651858.cd009157.pub2. CrossRef
Suissa S, Dell’Aniello S, Ernst P. Long-acting bronchodilator initiation in COPD and the risk of adverse cardiopulmonary events a population-based comparative safety study. Chest. 2017;151(1):60–7. https://doi.org/10.1016/j.chest.2016.08.001. CrossRefPubMed
Kawayama T, Hoshino T, Ichiki M, Tsuda T, Kinoshita M, Takata S, Koga T, Iwanaga T, Aizawa H, Kurume CSG. Effect of add-on therapy of tiotropium in COPD treated with theophylline. Int J Chronic Obstr Pulm Dis. 2008;3(1):137–47.
Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol. 2009;4:435–59. https://doi.org/10.1146/annurev.pathol.4.110807.092145. CrossRefPubMed
Chrystyn H, Mulley BA, Peake MD. Dose response relation to oral theophylline in severe chronic obstructive airways disease. BMJ. 1988;297(6662):1506–10. CrossRef
Kidney J, Dominguez M, Taylor PM, Rose M, Chung KF, Barnes PJ. Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy. Am J Respir Crit Care Med. 1995;151(6):1907–14. https://doi.org/10.1164/ajrccm.151.6.7767539. CrossRefPubMed
Culpitt SV, de Matos C, Russell RE, Donnelly LE, Rogers DF, Barnes PJ. Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;165(10):1371–6. CrossRef
- Effects of Tiotropium Combined with Theophylline on Stable COPD Patients of Group B, D and its Impact on Small Airway Function: A Randomized Controlled Trial
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II